To the top

Page Manager: Webmaster
Last update: 9/11/2012 3:13 PM

Tell a friend about this page
Print version

Immunotherapeutic strateg… - University of Gothenburg, Sweden Till startsida
Sitemap
To content Read more about how we use cookies on gu.se

Immunotherapeutic strategies for relapse control in acute myeloid leukemia

Journal article
Authors Anna Martner
Fredrik Bergh Thorén
Johan Aurelius
Kristoffer Hellstrand
Published in Blood Reviews
Volume 27
Issue 5
Pages 209-216
ISSN 0268-960X
Publication year 2013
Published at Sahlgrenska Cancer Center
Pages 209-216
Language en
Links dx.doi.org/10.1016/j.blre.2013.06.0...
Keywords Acute myeloid leukemia, Maintenance therapy, Leukemia-related immunosuppression, REGULATORY T-CELLS, ACUTE MYELOGENOUS LEUKEMIA, BONE-MARROW-TRANSPLANTATION, POST-CONSOLIDATION IMMUNOTHERAPY, REMISSION, MAINTENANCE THERAPY, ACUTE PROMYELOCYTIC LEUKEMIA, KIR LIGAND, INCOMPATIBILITY, HUMORAL IMMUNE-RESPONSES, 1ST COMPLETE REMISSION, LOW-DOSE INTERLEUKIN-2
Subject categories Cancer and Oncology

Abstract

Despite that the initial phases of chemotherapy induce disappearance of leukemic cells in many patients with acute myeloid leukemia (AML), the prevention of life-threatening relapses in the post-remission phase remains a significant clinical challenge. Allogeneic bone marrow transplantation, which is available for a minority of patients, efficiently prevents recurrences of leukemia by inducing immune-mediated elimination of leukemic cells, and over the past decades, numerous immunotherapeutic protocols have been developed aiming to mimic the graft-versus-leukemia reaction for the prevention of relapse. Here we review past and present strategies for relapse control with focus on overcoming leukemia-related immunosuppression in AML. We envisage future treatment protocols, in which systemic immune activators, such as vaccines, dendritic cell-based therapies, engineered variants of IL-2, or IL-15, are combined with agents that counter immunosuppression mediated by, e.g., the PD/PDL interaction, CTLA-4, CD200, reactive oxygen species, IDO expression, CXCR4, or the KIR/class I interaction, based on characteristics of the prevailing malignant clone. This combinatorial approach may pave the way for individualized immunotherapy in AML.

Page Manager: Webmaster|Last update: 9/11/2012
Share:

The University of Gothenburg uses cookies to provide you with the best possible user experience. By continuing on this website, you approve of our use of cookies.  What are cookies?